

REGENERON PHARMACEUTICALS INC
Form 8-K
June 27, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2011 (June 25, 2011)

REGENERON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

| | | |
|---|-----------------------|-----------------------------------|
| New York | 000-19034 | 13-3444607 |
| (State or other jurisdiction of Incorporation) | (Commission File No.) | (IRS Employer Identification No.) |

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of principal executive offices, including zip code)

(914) 347-7000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure.

On April 26, 2011, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the Phase 3 VELOUR trial evaluating the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen [folinic acid (leucovorin), 5-fluorouracil, and irinotecan] versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival (OS) in the second-line treatment of metastatic colorectal cancer (mCRC). On June 25, 2011, at the ESMO World Congress on Gastrointestinal Cancer in Barcelona, Spain, data were presented related to the results of the VELOUR trial. A copy of the slides that were presented is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

| | |
|------|---|
| 99.1 | Presentation entitled Intravenous (IV) Aflibercept Versus Placebo in Combination With Irinotecan/5-FU (FOLFIRI) For Second-line Treatment of Metastatic Colorectal Cancer (mCRC): Results Of A Multinational Phase III Trial. |
|------|---|

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 27, 2011

REGENERON PHARMACEUTICALS, INC.

By: /s/ Murray A Goldberg
Name: Murray A. Goldberg
Title: Senior Vice President, Finance and
Administration, Chief Financial Officer, Treasurer,
and Assistant Secretary

Exhibit Index

| Number | Description |
|--------|---|
| 99.1 | Presentation entitled Intravenous (IV) Aflibercept Versus Placebo in Combination With Irinotecan/5-FU (FOLFIRI) For Second-line Treatment of Metastatic Colorectal Cancer (mCRC): Results Of A Multinational Phase III Trial. |
